Finally, these data suggest that cannabigerol and IFN-γ exert their anti-cancer properties via the inhibition of STAT3 (upregulated by IL-11 and LIF) and c-Jun/AP-1 (downregulated by Pentraxin2/SAP), respectively. Here, STAT3 is linked to cancer.